The pathogenic role of T-cell–derived cytokines in psoriasis has led to considerable interest in exploring T-cell–specific calcineurin inhibitors in its treatment.
1,2 Cyclosporine is approved by the US Food and Drug Administration (FDA) to treat recalcitrant chronic plaque psoriasis in nonimmunosuppressed patients at an oral dose of 2.5 to 5.0 mg/kg/d.
3 Several attempts to use topical cyclosporine in varying dose regimens (0.1%-10% weight by weight [w/w]), in different topical vehicles, have failed to yield expected clinical response in treatment of various inflammatory dermatoses, including psoriasis.
4-10 This has been attributed to the poor topical absorption resulting from the unfavorable physicochemical properties of the drug, such as poor aqueous solubility, large molecular weight, and high lipophilicity.
9,11,12